{"slug":"japan","tag":"japan","variants":["japan"],"description":"No description yet","count":7,"kinds":{"person":7},"related":[{"slug":"leadership","tag":"leadership","shared":2},{"slug":"clinician-scientist","tag":"clinician-scientist","shared":1},{"slug":"discovery","tag":"discovery","shared":1},{"slug":"esophageal","tag":"esophageal","shared":1},{"slug":"gastric","tag":"gastric","shared":1},{"slug":"hcc","tag":"hcc","shared":1},{"slug":"hospital-management","tag":"hospital-management","shared":1},{"slug":"immunology","tag":"immunology","shared":1},{"slug":"immunotherapy","tag":"immunotherapy","shared":1},{"slug":"neuro-oncology","tag":"neuro-oncology","shared":1},{"slug":"oncolytic-virus","tag":"oncolytic-virus","shared":1},{"slug":"regulatory-t-cells","tag":"regulatory-t-cells","shared":1}],"records":[{"id":"takashi-kamei","kind":"person","name":"Takashi Kamei","route":"/people/takashi-kamei/","tldr":"Director of Tohoku University Hospital, the leading university hospital and cancer genomic medicine hub for the Tohoku region of Japan."},{"id":"nariaki-matsuura","kind":"person","name":"Nariaki Matsuura","route":"/people/nariaki-matsuura/","tldr":"President of the Osaka International Cancer Institute, the Osaka prefectural cancer centre that relocated to a new hospital in central Osaka in 2017."},{"id":"ken-kato","kind":"person","name":"Ken Kato","route":"/people/ken-kato/","tldr":"Japanese oncologist who led ATTRACTION-3 and KEYNOTE-590, bringing immunotherapy to oesophageal cancer."},{"id":"mitsuru-sasako","kind":"person","name":"Mitsuru Sasako","route":"/people/mitsuru-sasako/","tldr":"Japanese surgeon whose JCOG trials defined D2 gastrectomy and adjuvant S-1 as standards for gastric cancer."},{"id":"masatoshi-kudo","kind":"person","name":"Masatoshi Kudo","route":"/people/masatoshi-kudo/","tldr":"Japanese hepatologist who led REFLECT, the trial that made lenvatinib a first-line option for liver cancer."},{"id":"shimon-sakaguchi","kind":"person","name":"Shimon Sakaguchi","route":"/people/shimon-sakaguchi/","tldr":"Discovered regulatory T cells, the immune cells that suppress anti-tumour responses and are now a target for cancer therapy."},{"id":"tomoki-todo","kind":"person","name":"Tomoki Todo","route":"/people/tomoki-todo/","tldr":"Tomoki Todo built the triple-mutated herpes virus that became the first oncolytic virus approved in Japan, and ran the trial in recurrent glioblastoma behind that approval."}]}